Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 27, 2024 USD ($)		Sep. 29, 2023 USD ($)		Sep. 27, 2024 USD ($) Defendent	Sep. 29, 2023 USD ($)
Net sales	$ 505.5		$ 497.0		$ 1,487.6	$ 1,396.6
Operating Income (Loss)	36.4		(282.0)		46.1	(441.2)
Depreciation and amortization	(18.0)		(125.6)		(66.1)	(388.1)
Employee Benefits and Share-based Compensation	1.5		(2.4)		(3.8)	(7.7)
Restructuring charges, net	(0.1)		0.1		(10.5)	(0.9)
Restructuring and related charges, net					(10.5)	(1.7)
Separation Costs	(15.2)		(142.1)		(32.2)	(157.3)
Bad Debt Expense, Customer Bankruptcy, Pre-Petition Amount					6.4	0.0
Interest Expense	(59.0)		(133.1)		(177.5)	(457.7)
Interest income	7.4		3.4		20.2	12.8
Other (expense) income, net	(3.8)		9.1		(3.6)	(6.7)
Reorganization items, net	0.0		(1,311.5)		0.0	(1,321.1)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(19.0)		(1,714.1)		$ (114.8)	(2,213.9)
Number of Reportable Segments | Defendent					2
Specialty Brands
Restructuring and related charges, net	(0.1)		0.0		$ (10.5)	0.0
Specialty Generics
Net sales	219.5		210.8		669.8	578.3
Corporate, Non-Segment
Corporate and unallocated expenses	(27.1)	[1]	(16.3)	[1]	(70.1)	(29.7)
Depreciation and amortization	(26.3)		(137.0)		(93.5)	(423.2)
Separation Costs	(15.2)		(142.1)		(32.2)	(157.3)
Operating Segments
Operating Income (Loss)	103.6		151.6		249.8	313.5
Operating Segments | Specialty Brands
Net sales	286.0		286.2		817.8	818.3
Operating Income (Loss)	51.6		87.6		97.2	181.6
Operating Segments | Specialty Generics
Net sales	219.5		210.8		669.8	578.3
Operating Income (Loss)	$ 52.0		$ 64.0		$ 152.6	$ 131.9

[1] Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.